B en e m i d, (p-[di-n-propylsulfamyl]-benzoic acid), is a potent inhibitor of the renal tubular transport systems responsible for tubular secretion of the penicillins (1-3), p-aminohippurate (1) , phenolsulfonphthalein (1) and p-aminosalicylic acid (4) . It was initially introduced as an agent more effective than carinamide in sustaining high therapeutic blood levels of penicillin and p-aminosalicylic acid.
Benemid also is a potent uricosuric agent, of low toxicity (5) . Gutman and Yu (6) , in studies on 39 patients with chronic gout maintained on a low purine, restricted protein diet, found that Benemid consistently caused a rapid and marked increase in urinary urate excretion and a sharp decline in serum urate levels. The mean rise in urinary urate excretion in the first week of Benemid administration was 67%o, 52% and 46% with daily doses of 2 gm., 1 gm. or 0.5 gm., respectively, resulting in corresponding falls in serum urate of 42%o, 33%o and 27%o. Talbott, Bishop, Norcross, and Lockie (7) have reported similar results. The drug appears to have an important place in the management of chronic gout (8) .
In the present study the renal mechanisms whereby the uricosuric action of Benemid is effected have been investigated. Simultaneous renal clearance studies of urate, inulin or endogenous creatinine, p-aminohippurate, sodium, potassium and chloride were carried out in 10 male gouty subjects before and after oral administration of 2 gin. of Benemid. In some of these subjects the effects of Benemid on phosphate clearance, urinary excretion of hydrogen and ammonium ion, and on urine and blood pH were also 1 Supported by grants from the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, U. S. Public Health Service; the American Heart Association; and the Sarah Welt Foundation.
studied. The implications of our findings in respect to the renal mechanisms for regulation of urate excretion by the kidneys in normal and gouty man are discussed.
METHODS
The subjects, whose ages ranged from 38 to 54 years, were all known to have had gout for several years. Only patients without overt cardiovascular and renal disease (no albuminuria, cylindruria, nitrogen retention) were used for these experiments. All had been on low purine, restricted protein (50-80 gm./day) diets preceding study and were in the morning post-absorptive state at the time of the experiment. Water was ingested in liberal quantities to maintain urine flow rates above 4 ml./min. throughout the experiment.
After drawing blood for inulin and p-aminohippurate plasma blank values, priming and sustaining infusions of these substances in 0.89% saline were administered by means of a Bowman constant infusion pump at rates calculated to maintain plasma concentrations of inulin at 30 mg.% and p-aminohippurate at 2 mg.%. Thirty minutes were allowed for equilibration. Bladder catheterization was then performed with multi-eyed hard rubber catheters and three 10-to 15- (9) .
In two additional subjects simultaneous endogenous creatinine, urate, sodium, potassium and chloride clearances were obtained at 30-minute periods for two hours preceding and two hours following administration of Benemid. In this manner intravenous infusions were avoided and urine could be collected by spontaneous voiding.
In two gouty subjects the effects of a single 2 gm. oral dose of Benemid upon simultaneous inulin, urate, endogenous creatinine and p-aminohippurate were studied over 24 hours. The drug was administered to these subjects following three 10-to 20-minute control periods, during which time urine was collected by catheter and bladder wash. Following administration of the drug, urines were collected by spontaneous voiding at two-hour intervals during the day and at two four-hour intervals at night. Intravenous infusions of inulin and p-aminohippurate were maintained for 24 hours employing the technique of Sirota, Baldwin and Villarreal (10) . Two bloods were drawn during the control periods, and six at strategically spaced intervals for 24 hours after drug ingestion. In a third subject the diurnal variations of endogenous creatinine, urate, sodium, potassium and chloride clearances were studied for 48 hours preceding Benemid and for 48 hours following a single 2 gm. oral dose. This patient was hospitalized and maintained on a constant protein (50 gm.), constant salt (3.5 gm.) diet for three days preceding the control study. Water was allowed ad lib. throughout. The control values represent the averages of three 10-to 15-minute periods. The values after Benemid represent the averages of six 20-minute periods starting immediately after oral ingestion of 2 gm. of the drug. * CCR, endogenous creatinine clearance, used instead of CIN in these subjects.
t These changes considered significant (p <.02). The t test of significance for the c!N-and Cc' ratios was applied to tceocIN to the six post-Benemid clearances as compared to the three control periods for each of the subjects. In the two patients so studied there were no significant effects of the drug upon urine or blood pH, urine titratable acidity and ammonium ion excretion. However, these latter observations were obtained without previously rendering the subjects acidotic, and with low control values (2 to 10, ,eq. hydrogen ion/min. and 10 to 19 ,ueq. ammonium ion/min.).
Prolonged experiments. Since the two-hour experiments lapsed before the uricosuric effect of Benemid had worn off, observations were prolonged over a 24-hour period in three gouty subjects in an attempt to establish the duration of increased CURATE following ingestion of a single 2 gm. dose ( Figure 1) In view of the indications of severe tubular damage in this patient, and the evidences of impaired reabsorption of glucose (renal glycosuria), amino acids (amino aciduria) and phosphate (hyperphosphaturia), it seemed more rational to ascribe the high urinary urate excretion to impaired tubular reabsorption of urate than to enhanced tubular secretion of urate. This interpretation was supported by the finding in this patient of a CURATE/CIN ratio of approximate unity (0.984), as compared with a normal mean CUIRATE/CIN ratio of 0.067, which would indicate both complete filtrability at the glomerulus and virtual absence of urate reabsorption by the tubules. In view of the concurrent evidence in this patient of generally reduced function of the proximal tubules, it may be inferred that urate normally is reabsorbed wholly or in large part by the proximal convoluted tubules. The fact that CURATE/CIN did not exceed unity argues against tubular secretion of urate.
In accord with these inferences is the striking fact that of all the non-gouty and gouty subjects to whom we have administered Benemid, this patient was the only one in whom the drug failed to evoke increased urinary urate excretion and increased urate clearance.
The renal mechanisms for urate excretion in gouty subjects do not appear to differ in any essential from those of normal man (24, 25) . However, in view of the often marked hyperuricemia in gout, complete filtrability of urate at the glomerulus cannot be assumed. We therefore subjected the sera of four of these patients, before treatment with Benemid, to ultrafiltration. The results, in conformity with those obtained in 13 other cases of gout (26) , showed the serum urate to be wholly filtrable, apart from variations within the limits of error of the method: in case A. R., serum urate 11.3 mg. % (expressed in terms of serum water), ultrafiltrate urate 11.6 mg. %o; in Case 0. G., serum urate 11.1 mg. %, ultrafiltrate 10.6 mg. % ; in Case M. M., serum urate 8.7 mg. %, ultrafiltrate 8.8 mg. %o; in Case H. H., serum urate 8.5 mg. %o, ultrafiltrate 7.8 mg. %o.
In view of these -findings tubular reabsorption of urate and not non-filtrability of plasma urate must be assumed to explain the large discrepancy between urate clearance and glomerular filtration rate in these patients. The possibility of some tubular excretion of urate in gout is not excluded.
Saturation of tubule reabsorptive capacity for urate probably does not occur either in normal subjects (22) There is every indication that, as in its effects on penicillin and p-aminosalicylic acid, Benemid produces uricosuria primarily by altering renal excretory mechanisms. The rapidity of the uricosuric effect, within 40 minutes of ingestion in most instances, makes it highly improbable that it can be accounted for by increased breakdown of nucleic acids, which normally have a slow turnover rate, or by accelerated urate biosynthesis. Moreover, studies carried out in two of our gouty subjects before, during and after ingestion of 2 gm. of Benemid showed no concurrent increase in urinary total nitrogen or phosphorus excretion (26). Bishop, Rand and Talbott (27) have demonstrated a decrease in the miscible pool of urate after administration of Benemid, indicating a predominantly excretory effect of the drug.
Our data indicate clearly that the enhancement of renal excretion of urate by Benemid is not due to an increase in glomerular filtration but is attributable to inhibition of tubular reabsorption of urate. In none of the subjects studied by us was this inhibition complete, the highest CURATE/CIN ratio obtained being 0.547. Since the drug exerts its effect upon known proximal tubule function (PSP, PAH, PAS and penicillin secretion) it appears likely that the uricosuric effect is mediated at this level of the nephron. It is interesting that the uricosuria produced by Benemid is the result of inhibition of a reabsorptive process whereas its other known effects are based upon inhibition of secretary mechanisms. The drug appeared to exert no effect upon phosphate reabsorption, the only other reabsorptive process with a Tm mechanism studied by us. Beyer and his associates (1), working with dogs, demonstrated that the drug exerted no effect upon the reabsorptive mechanisms for glucose, arginine, sulfonamides, urea and phosphate. The precise mechanism of the inhibitory effect of Benemid on tubular urate reabsorption has not been determined. According to Beyer and co-workers (1), the drug, in concentrations which suppress PAH, PSP, PAS, penicillin and urate transport, will inhibit utilization of energy from high-energy phosphate bonds without interfering with oxygen uptake or phosphorylation.
Significant depression of CPAH occurred following Benemid admininstration in eight of the 10 subjects so studied. From the data in Table I In the acute studies several of the subjects showed significant increases in the clearances of either sodium or chloride, or in both of these ions. However, the absolute magnitude of the renal clearances of these ions was so low that a slight increment would result in a marked increase in their clearance when expressed as per cent change. Thus (30) . Unless water diuresis is encouraged during Benemid uricosuria excessively high concentrations of urate may be encountered in the urine. Thus, in one of our subjects on the 24-hour study maintained on fluids ad lib., a concentration of urine urate of 157 mg. % was obtained at a time when his urine flow was less than 1 ml./min. Talbott and Coombs (31) found a maximum urate solubility of slightly more than 100 mg./100 ml. in the urine of gouty subjects. Alkalinization and water diuresis would therefore appear to be important measures for the prevention of uric acid crystalluria during Benemid therapy. In a gouty subject with normal glomerular function and a plasma urate concentration of 8 mg. %o, a urine flow of at least 4 ml./min. is necessary to maintain urine urate concentrations under 100 mg./100 ml. during the peak of Benemid uricosuria, which occurs within four hours after drug administration.
No indication of toxicity attributable to Benemid was observed in the course of these experiments, with the possible exception of one patient who developed an acute attack of gout the day after. The effects upon renal transport mechanisms are completely reversible following discontinuance of medication. Benemid appears thus far to be of a low order of toxicity (6, 32) and no overt signs of renal "irritation" (albuminuria, casts, red blood cells) unequivocally attributable to the drug have yet been reported. SUMMARY 1. In 15 clearance studies carried out in 13 gouty subjects, Benemid given orally in a single 2 gm. dose consistently produced a marked rise in urate clearance, from a mean control level of 7.99 ml./min. to a mean peak value of 32.7 ml./ min. This rise was usually evident within 40 minutes of drug administration and lasted 24 hours in the subjects followed for this period. The plasma urate level fell concomitantly.
2. There was no significant effect on glomerular filtration rate. The ratio CURATE/GFR consequently rose, from a mean control value of 0.0718 to peak values averaging 0.333. 3. Some depression of CPAH, with consequent moderate rise in the ratio CIN/PPAH, was observed in most instances.
4. Phosphate and potassium clearances were unaffected by Benemid. Slight but significant increases in sodium or chloride clearance, or both, occurred in about half the subjects. 5 . A marked diurnal variation in CURATE/GFR ratios was noted in those subjects in whom these functions were studied over one or more 24-hour periods. The depression of these ratios noted during sleeping hours persisted in spite of continued overall Benemid uricosuria.
6. The data obtained support the complete filtration-partial tubular reabsorption concept of urate excretion in the normal and gouty subject and indicate that Benemid uricosuria is the result of a highly selective inhibition of tubular reabsorption of filtered urate. Corroboratory evidence for this conclusion was derived by clearance studies in one subject with glomerulo-tubular imbalance of the Fanconi type who was found to have a CuRATE/CIN ratio of approximate unity, which was uninfluenced by Benemid.
